Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1965 1
1966 1
1967 1
1969 1
1970 2
1971 1
1972 1
1974 2
1975 3
1976 2
1977 4
1978 4
1979 3
1980 5
1981 2
1982 5
1983 3
1984 8
1985 7
1986 7
1987 13
1988 12
1989 11
1990 7
1991 10
1992 12
1993 12
1994 17
1995 17
1996 13
1997 18
1998 19
1999 21
2000 25
2001 26
2002 15
2003 28
2004 25
2005 20
2006 22
2007 31
2008 33
2009 37
2010 36
2011 52
2012 43
2013 49
2014 49
2015 54
2016 52
2017 48
2018 59
2019 46
2020 107
2021 106
2022 110
2023 86
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

1,264 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypogonadotropic hypogonadism 15 with or without anosmia"
Page 1
Cardiovascular Safety of Testosterone-Replacement Therapy.
Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM Jr, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE; TRAVERSE Study Investigators. Lincoff AM, et al. N Engl J Med. 2023 Jul 13;389(2):107-117. doi: 10.1056/NEJMoa2215025. Epub 2023 Jun 16. N Engl J Med. 2023. PMID: 37326322 Clinical Trial.
BACKGROUND: The cardiovascular safety of testosterone-replacement therapy in middle-aged and older men with hypogonadism has not been determined. METHODS: In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 m …
BACKGROUND: The cardiovascular safety of testosterone-replacement therapy in middle-aged and older men with hypogonadism has not been …
Gynecomastia and hormones.
Sansone A, Romanelli F, Sansone M, Lenzi A, Di Luigi L. Sansone A, et al. Endocrine. 2017 Jan;55(1):37-44. doi: 10.1007/s12020-016-0975-9. Epub 2016 May 4. Endocrine. 2017. PMID: 27145756 Review.
Adipose Tissue Dysfunction and Obesity-Related Male Hypogonadism.
Genchi VA, Rossi E, Lauriola C, D'Oria R, Palma G, Borrelli A, Caccioppoli C, Giorgino F, Cignarelli A. Genchi VA, et al. Int J Mol Sci. 2022 Jul 25;23(15):8194. doi: 10.3390/ijms23158194. Int J Mol Sci. 2022. PMID: 35897769 Free PMC article. Review.
In addition, androgen deficiency could further accelerate adipose tissue expansion and therefore exacerbate obesity, which in turn enhances hypogonadism, thus inducing a vicious cycle. Based on these considerations, we propose an overview on the relationship of adipose tis …
In addition, androgen deficiency could further accelerate adipose tissue expansion and therefore exacerbate obesity, which in turn enhances …
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study.
Bhasin S, Lincoff AM, Basaria S, Bauer DC, Boden WE, Cunningham GR, Davey D, Dubcenco E, Fukumoto S, Garcia M, Granger CB, Kalahasti V, Khera M, Miller MG, Mitchell LM, O'Leary MP, Pencina KM, Snyder PJ, Thompson IM Jr, Travison TG, Wolski K, Nissen SE; TRAVERSE Study Investigators. Bhasin S, et al. Am Heart J. 2022 Mar;245:41-50. doi: 10.1016/j.ahj.2021.11.016. Epub 2021 Dec 4. Am Heart J. 2022. PMID: 34871580 Free article. Clinical Trial.
Neither the long-term efficacy nor safety of testosterone treatment has been studied in an adequately-powered randomized trial. METHODS: The Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVER …
Neither the long-term efficacy nor safety of testosterone treatment has been studied in an adequately-powered randomized trial …
Use of platelet-rich plasma for COVID-19-related olfactory loss: a randomized controlled trial.
Yan CH, Jang SS, Lin HC, Ma Y, Khanwalkar AR, Thai A, Patel ZM. Yan CH, et al. Int Forum Allergy Rhinol. 2023 Jun;13(6):989-997. doi: 10.1002/alr.23116. Epub 2022 Dec 21. Int Forum Allergy Rhinol. 2023. PMID: 36507615 Free PMC article. Clinical Trial.
INTRODUCTION: The current study evaluated the use of platelet-rich plasma (PRP), an autologous blood product with supraphysiologic concentrations of growth factors, in the treatment of prolonged coronavirus disease 2019 (COVID-19)-related smell loss. METHODS: This multi-instituti …
INTRODUCTION: The current study evaluated the use of platelet-rich plasma (PRP), an autologous blood product with supraphysiologic concentra …
Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis.
Christou MA, Christou PA, Markozannes G, Tsatsoulis A, Mastorakos G, Tigas S. Christou MA, et al. Sports Med. 2017 Sep;47(9):1869-1883. doi: 10.1007/s40279-017-0709-z. Sports Med. 2017. PMID: 28258581 Review.
Studies were included when the following criteria were fulfilled: participants were athletes or recreational users of any age, sex, level or type of sport; AAS use of any type, dose, form or duration; AAS effects on the reproductive system were assessed as stated by medical histo …
Studies were included when the following criteria were fulfilled: participants were athletes or recreational users of any age, sex, level or …
Testosterone, Hypogonadism, and Heart Failure.
Di Lodovico E, Facondo P, Delbarba A, Pezzaioli LC, Maffezzoni F, Cappelli C, Ferlin A. Di Lodovico E, et al. Circ Heart Fail. 2022 Jul;15(7):e008755. doi: 10.1161/CIRCHEARTFAILURE.121.008755. Epub 2022 Apr 8. Circ Heart Fail. 2022. PMID: 35392658 Review.
Herein, we critically review published studies relating to testosterone, hypogonadism, and HF and provide practical clinical information on proper diagnosis and treatment of male hypogonadism in patients with HF. ...Nevertheless, by selecting the few methodol …
Herein, we critically review published studies relating to testosterone, hypogonadism, and HF and provide practical clinical i …
Hypogonadism and diabetes.
Betancourt-Albrecht M, Cunningham GR. Betancourt-Albrecht M, et al. Int J Impot Res. 2003 Aug;15 Suppl 4:S14-20. doi: 10.1038/sj.ijir.3901031. Int J Impot Res. 2003. PMID: 12934046 Review.
Pharmacological management of late-onset hypogonadism.
Rastrelli G, Maggi M, Corona G. Rastrelli G, et al. Expert Rev Clin Pharmacol. 2018 Apr;11(4):439-458. doi: 10.1080/17512433.2018.1445969. Epub 2018 Mar 5. Expert Rev Clin Pharmacol. 2018. PMID: 29505313 Review.
The frequency of late-onset hypogonadism (LOH) ranges between 2 and 15%. Up to 85% of LOH is due to a functional impairment of the hypothalamus-pituitary-testicular axis, mostly secondary to metabolic conditions. Areas covered: This paper provides a comprehensive re …
The frequency of late-onset hypogonadism (LOH) ranges between 2 and 15%. Up to 85% of LOH is due to a functional impairment of …
Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S, Travison TG, Pencina KM, O'Leary M, Cunningham GR, Lincoff AM, Nissen SE, Lucia MS, Preston MA, Khera M, Khan N, Snabes MC, Li X, Tangen CM, Buhr KA, Thompson IM Jr. Bhasin S, et al. JAMA Netw Open. 2023 Dec 1;6(12):e2348692. doi: 10.1001/jamanetworkopen.2023.48692. JAMA Netw Open. 2023. PMID: 38150256 Free PMC article. Clinical Trial.
OBJECTIVE: To compare the effect of TRT vs placebo on the incidences of high-grade prostate cancers (Gleason score 4 + 3), any prostate cancer, acute urinary retention, invasive prostate procedures, and pharmacologic treatment for lower urinary tract symptoms in men with hypog …
OBJECTIVE: To compare the effect of TRT vs placebo on the incidences of high-grade prostate cancers (Gleason score 4 + 3), any prostate canc …
1,264 results